Clinical Scorecard: FDA updates PAH label with trial data
At a Glance
| Category | Detail |
|---|---|
| Condition | Pulmonary Arterial Hypertension |
| Key Mechanisms | Sotatercept improves exercise capacity and functional class, reduces risk of clinical worsening events. |
| Target Population | Adults recently diagnosed with pulmonary arterial hypertension (WHO Group 1), functional class II or III. |
| Care Setting | Clinical trial setting, phase 3 HYPERION trial. |
Key Highlights
- Sotatercept reduced risk of clinical worsening events by 76% compared to placebo.
- Primary efficacy endpoint was time to first confirmed clinical worsening event.
- Common adverse reactions included epistaxis, telangiectasia, and increased hemoglobin.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of pulmonary arterial hypertension within 12 months of screening.
Management
- Sotatercept is approved for improving exercise capacity and reducing clinical worsening.
Monitoring & Follow-up
- Monitor hemoglobin and platelet levels before each of the first 5 doses and periodically thereafter.
Risks
- Contraindicated in patients with serious hypersensitivity to sotatercept-csrk or its excipients.
Patient & Prescribing Data
320 adults with WHO functional class II or III pulmonary arterial hypertension.
72% received double background therapy, 28% triple therapy, and 17% prostacyclin infusion therapy.
Clinical Best Practices
- Consider the risk of epistaxis when prescribing sotatercept.
- Discontinue treatment if serious adverse reactions occur.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
